Drug Information Request (DIR)

Hematological Safety Analysis & Clinical Evidence

Clinical Inquiry

"Does Cerebrolysin administration result in clinically significant platelet reduction or dysfunction, and what hematological monitoring is evidenced in current literature?"

Department ICU

Responder Dr. Ahmed Khaled - DIC

Reference ID DIR-2026-CERE-09

Date of Issue February 09, 2026

Evidence-Based Findings

Platelet Count & Morphology

Stability Case reports confirm coagulograms and full blood counts remain within physiological limits during active infusion [2, 44].

Morphology Isolated reports of "platelet size decrease" lack association with absolute count reduction or bleeding events [31].

ADR Profile WHO-VigiAccess analysis identifies neuro/GI effects but does not categorize thrombocytopenia as a frequent ADR for Cerebrolysin [24, 46].

Hemostatic Function

Aggregation Multiplate platelet function tests demonstrate no functional disturbances or inhibition of aggregation integrity [14].

Thresholds Clinical trials (e.g., CLINCH) use a baseline of 75,000/µL as an exclusion safety bar, not a predicted therapeutic outcome [12].

Coagulation No documented interference with standard coagulation pathways or potentiation of antiplatelet therapies [15].

Trial-Based Safety Metrics

General Categorized as "Safe and Well-Tolerated" in major CARS and CASTA trial populations [4, 5, 18].

SAE Analysis Cochrane review (2019) noted numerical increases in non-fatal SAEs, though none were specifically hematological or platelet-related [6, 45].

Monitoring Recommendations

Standard baseline Full Blood Count (FBC) prior to initiation.

Routine hematological monitoring as per standard stroke unit protocols.

Clinical vigilance for signs of bleeding/ecchymosis (SAE Framework).

Final DIR Summary & Clinical Guidance

Conclusion: Current clinical evidence does not support a causal link between Cerebrolysin and thrombocytopenia or platelet dysfunction.

Guidance: Therapy should not be discontinued based on isolated or asymptomatic laboratory fluctuations. Management should be dictated by the Serious Adverse Event (SAE) protocol, focusing on clinical symptoms (e.g., bleeding) rather than arbitrary platelet count thresholds.